Cargando…
Prevalence of dyslipidemia and its association with opium consumption in the Rafsanjan cohort study
The potential effects of opium consumption on lipid profile remain unquantified. We considered the association between opium use and dyslipidemia. In this cross-sectional study, we used data obtained from the Rafsanjan cohort study, as a part of the prospective epidemiological research studies in Ir...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262952/ https://www.ncbi.nlm.nih.gov/pubmed/35798768 http://dx.doi.org/10.1038/s41598-022-13926-3 |
_version_ | 1784742617909559296 |
---|---|
author | Jamali, Zahra Noroozi Karimabad, Mojgan Khalili, Parvin Sadeghi, Tabandeh Sayadi, Ahmadreza Mohammadakbari Rostamabadi, Faegheh La Vecchia, Carlo Esmaeili-Nadimi, Ali |
author_facet | Jamali, Zahra Noroozi Karimabad, Mojgan Khalili, Parvin Sadeghi, Tabandeh Sayadi, Ahmadreza Mohammadakbari Rostamabadi, Faegheh La Vecchia, Carlo Esmaeili-Nadimi, Ali |
author_sort | Jamali, Zahra |
collection | PubMed |
description | The potential effects of opium consumption on lipid profile remain unquantified. We considered the association between opium use and dyslipidemia. In this cross-sectional study, we used data obtained from the Rafsanjan cohort study, as a part of the prospective epidemiological research studies in IrAN (PERSIAN) with detailed and validated data on opium consumption and selected other exposures. A total of 9932 adults were included in the study. Logistic regression models were used to assess the relationships of opium consumption with the prevalence of dyslipidemia and lipid disorders. In this population, 73.33% had dyslipidemia and the prevalence rates of high TC, high TG, high LDL and low HDL were 54.24%, 47.45%, 34.43% and 11.91% respectively. After adjustment for all confounders, opium users compared with non-users had lower odds ratios (OR) of high TC and high LDL [0.81 (95% confidence interval, CI 0.71–0.92) and 0.80 (95% CI 0.69–0.93) respectively] and greater OR of low HDL [1.30 (95% CI 1.04–1.62)]. Longer duration of opium consumption resulted in lower ORs of high TC, 0.68 (95% CI 0.55–0.84) and high LDL, 0.82 (95% CI 0.67–0.99), and shorter duration of opium consumption resulted in increased odds of low HDL, 1.30 (95% CI 1.02–1.66). High dose of opium consumption was associated with an OR of dyslipidemia of 0.80 (95% CI 0.65–0.97), high TC of 0.80 (95% CI 0.67–0.95), and high LDL of 0.78 (95% CI 0.64–0.96) and low dose of opium consumption, with an OR of low HDL of 1.30 (95% CI 1.02–1.65). In relation to route of consumption, opium smoking was a risk factor for low HDL with an adjusted odds ratio of 1.31 (1.04–1.63). Opium use was associated with selected changes on serum lipid levels, but opium users had higher frequency of cardiovascular disease history. |
format | Online Article Text |
id | pubmed-9262952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-92629522022-07-09 Prevalence of dyslipidemia and its association with opium consumption in the Rafsanjan cohort study Jamali, Zahra Noroozi Karimabad, Mojgan Khalili, Parvin Sadeghi, Tabandeh Sayadi, Ahmadreza Mohammadakbari Rostamabadi, Faegheh La Vecchia, Carlo Esmaeili-Nadimi, Ali Sci Rep Article The potential effects of opium consumption on lipid profile remain unquantified. We considered the association between opium use and dyslipidemia. In this cross-sectional study, we used data obtained from the Rafsanjan cohort study, as a part of the prospective epidemiological research studies in IrAN (PERSIAN) with detailed and validated data on opium consumption and selected other exposures. A total of 9932 adults were included in the study. Logistic regression models were used to assess the relationships of opium consumption with the prevalence of dyslipidemia and lipid disorders. In this population, 73.33% had dyslipidemia and the prevalence rates of high TC, high TG, high LDL and low HDL were 54.24%, 47.45%, 34.43% and 11.91% respectively. After adjustment for all confounders, opium users compared with non-users had lower odds ratios (OR) of high TC and high LDL [0.81 (95% confidence interval, CI 0.71–0.92) and 0.80 (95% CI 0.69–0.93) respectively] and greater OR of low HDL [1.30 (95% CI 1.04–1.62)]. Longer duration of opium consumption resulted in lower ORs of high TC, 0.68 (95% CI 0.55–0.84) and high LDL, 0.82 (95% CI 0.67–0.99), and shorter duration of opium consumption resulted in increased odds of low HDL, 1.30 (95% CI 1.02–1.66). High dose of opium consumption was associated with an OR of dyslipidemia of 0.80 (95% CI 0.65–0.97), high TC of 0.80 (95% CI 0.67–0.95), and high LDL of 0.78 (95% CI 0.64–0.96) and low dose of opium consumption, with an OR of low HDL of 1.30 (95% CI 1.02–1.65). In relation to route of consumption, opium smoking was a risk factor for low HDL with an adjusted odds ratio of 1.31 (1.04–1.63). Opium use was associated with selected changes on serum lipid levels, but opium users had higher frequency of cardiovascular disease history. Nature Publishing Group UK 2022-07-07 /pmc/articles/PMC9262952/ /pubmed/35798768 http://dx.doi.org/10.1038/s41598-022-13926-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Jamali, Zahra Noroozi Karimabad, Mojgan Khalili, Parvin Sadeghi, Tabandeh Sayadi, Ahmadreza Mohammadakbari Rostamabadi, Faegheh La Vecchia, Carlo Esmaeili-Nadimi, Ali Prevalence of dyslipidemia and its association with opium consumption in the Rafsanjan cohort study |
title | Prevalence of dyslipidemia and its association with opium consumption in the Rafsanjan cohort study |
title_full | Prevalence of dyslipidemia and its association with opium consumption in the Rafsanjan cohort study |
title_fullStr | Prevalence of dyslipidemia and its association with opium consumption in the Rafsanjan cohort study |
title_full_unstemmed | Prevalence of dyslipidemia and its association with opium consumption in the Rafsanjan cohort study |
title_short | Prevalence of dyslipidemia and its association with opium consumption in the Rafsanjan cohort study |
title_sort | prevalence of dyslipidemia and its association with opium consumption in the rafsanjan cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262952/ https://www.ncbi.nlm.nih.gov/pubmed/35798768 http://dx.doi.org/10.1038/s41598-022-13926-3 |
work_keys_str_mv | AT jamalizahra prevalenceofdyslipidemiaanditsassociationwithopiumconsumptionintherafsanjancohortstudy AT noroozikarimabadmojgan prevalenceofdyslipidemiaanditsassociationwithopiumconsumptionintherafsanjancohortstudy AT khaliliparvin prevalenceofdyslipidemiaanditsassociationwithopiumconsumptionintherafsanjancohortstudy AT sadeghitabandeh prevalenceofdyslipidemiaanditsassociationwithopiumconsumptionintherafsanjancohortstudy AT sayadiahmadreza prevalenceofdyslipidemiaanditsassociationwithopiumconsumptionintherafsanjancohortstudy AT mohammadakbarirostamabadifaegheh prevalenceofdyslipidemiaanditsassociationwithopiumconsumptionintherafsanjancohortstudy AT lavecchiacarlo prevalenceofdyslipidemiaanditsassociationwithopiumconsumptionintherafsanjancohortstudy AT esmaeilinadimiali prevalenceofdyslipidemiaanditsassociationwithopiumconsumptionintherafsanjancohortstudy |